Virios Therapeutics, Inc. VIRI
We take great care to ensure that the data presented and summarized in this overview for Virios Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VIRI
View all-
Geode Capital Management, LLC Boston, MA231KShares$1.02 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA209KShares$927,4400.0% of portfolio
-
Ubs Group Ag186KShares$826,1150.0% of portfolio
-
Hrt Financial LP New York, NY81.6KShares$362,1880.0% of portfolio
-
Two Sigma Securities, LLC New York, NY53.4KShares$237,0600.0% of portfolio
-
State Street Corp Boston, MA52.8KShares$234,5560.0% of portfolio
-
Garden State Investment Advisory Services LLC Red Bank, NJ52KShares$230,8800.0% of portfolio
-
Mc Collum Christoferson Group LLC Amherst, NY33.5KShares$148,7400.0% of portfolio
-
Raymond James & Associates St Petersburg, FL30.6KShares$135,8640.0% of portfolio
-
Jane Street Group, LLC New York, NY28KShares$124,4620.0% of portfolio
Latest Institutional Activity in VIRI
Top Purchases
Top Sells
About VIRI
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Insider Transactions at VIRI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 21
2023
|
William Pridgen |
BUY
Open market or private purchase
|
Indirect |
15,335
+22.76%
|
$15,335
$1.3 P/Share
|
|
Aug 17
2023
|
Gregory Scott Duncan CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
25,000
+30.32%
|
$25,000
$1.25 P/Share
|
|
Dec 08
2022
|
Richard James Whitley |
SELL
Open market or private sale
|
Direct |
1,800
-72.0%
|
$0
$0.26 P/Share
|
|
May 23
2022
|
Gregory Scott Duncan CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
7,500
+18.77%
|
$30,000
$4.52 P/Share
|
|
May 23
2022
|
Angela Walsh SVP OF FINANCE |
BUY
Open market or private purchase
|
Indirect |
2,000
+40.0%
|
$8,000
$4.58 P/Share
|
|
May 18
2022
|
William Pridgen |
BUY
Open market or private purchase
|
Indirect |
241
+0.65%
|
$964
$4.5 P/Share
|
|
May 18
2022
|
Richard James Whitley |
BUY
Open market or private purchase
|
Direct |
500
+16.67%
|
$2,000
$4.53 P/Share
|
|
May 17
2022
|
William Pridgen |
BUY
Open market or private purchase
|
Indirect |
13,450
+26.94%
|
$53,800
$4.38 P/Share
|
|
Mar 29
2022
|
William Pridgen |
BUY
Open market or private purchase
|
Indirect |
600
+2.54%
|
$2,400
$4.94 P/Share
|
|
Mar 23
2022
|
William Pridgen |
BUY
Open market or private purchase
|
Indirect |
2,197
+8.93%
|
$10,985
$5.46 P/Share
|
|
Jan 27
2022
|
William Pridgen |
BUY
Open market or private purchase
|
Indirect |
4,180
+18.25%
|
$20,900
$5.98 P/Share
|
|
Jan 07
2022
|
Rosa Abel De La |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$20,000
$5.9 P/Share
|
|
Jan 06
2022
|
Richard James Whitley |
BUY
Open market or private purchase
|
Direct |
1,800
+47.37%
|
$9,000
$5.72 P/Share
|
|
Jan 04
2022
|
David R Keefer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$25,000
$5.8 P/Share
|
|
Jan 04
2022
|
John C Thomas |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$5,000
$5.65 P/Share
|
|
Jan 03
2022
|
William Pridgen |
BUY
Open market or private purchase
|
Indirect |
2,215
+13.22%
|
$11,075
$5.43 P/Share
|
|
Dec 23
2021
|
Richard James Whitley |
BUY
Open market or private purchase
|
Direct |
200
+50.0%
|
$1,000
$5.72 P/Share
|
|
Dec 21
2021
|
Gregory Scott Duncan CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
5,000
+16.69%
|
$25,000
$5.52 P/Share
|
|
Dec 21
2021
|
William Pridgen |
BUY
Open market or private purchase
|
Indirect |
8,827
+41.73%
|
$44,135
$5.66 P/Share
|
|
Jul 07
2021
|
William Pridgen |
BUY
Open market or private purchase
|
Direct |
942
+0.13%
|
$5,652
$6.32 P/Share
|